Table 2 Clinical effects and adverse events of T cell receptor gene-modified T cell therapies
Antigen | Type of cancer | Type of T cell receptor | Effects | Adverse events | Year of report | Reporter [reference] |
|---|---|---|---|---|---|---|
MART-1 | Malignant melanoma | Wild type | 1/15 PR | Fever, fatigue et al. | 2006 | Duval et al. [81] |
MART-1 | Malignant melanoma | Wild type | 2/17 PR | Not reported | 2006 | Morgan et al. [70] |
MART-1 | Malignant melanoma | High affinity | 66/20 PR | Disorders of the skin, eye, and inner ear | 2009 | Johnson et al. [71] |
MART-1 | Malignant melanoma | High-affinity modification | 9/13 tumor regression | Respiratory failure | 2014 | Chodon et al. [82] |
gp100 | Malignant melanoma | Mouse origin | 1/16 CR, 2/16 PR | Not reported | 2010 | Davis et al. [83] |
p53 | Breast cancer, esophageal cancer, malignant melanoma | Mouse origin | 1/10 PR | Not reported | 2010 | Davis et al. [83] |
CEA | Colon cancer | Mouse origin | 1/3 PR | Colitis | 2011 | Parkhurst et al. [84] |
NY-ESO-1 | Malignant melanoma | High-affinity modification | 2/11 CR, 3/11 PR, | GVHD, Skin erythema, diarrhea, decrease in blood pressure | 2011 | Robbins et al. [85] |
Synovial sarcoma | 4/6 PR | Â | Â | |||
Myeloma | 14/20 CR, 4/20 PR | 2015 | Rapoport et al. [86] | |||
MAGE-A3 | Malignant melanoma, myeloma | High-affinity modification | Not evaluated | Cardiogenic shock (death) | 2013 | Cameron et al. [87] |
MAGE-A4 | Esophageal cancer | Wild type | 3/10 long survival | Not reported | 2015 | Kageyamama et al. [88] |
WT-1 | MDS, AML | Wild type | 2/8 transient blast loss | Not reported | 2017 | Tawara et al. [89] |
Tyrosinase | Malignant melanoma | Wild type | 1/3 PR | Vitiligo | 2018 | Moore et al. [90] |